IDEMIA’s MorphoWaveTM Technology Demonstrates Full Interoperability and Surpasses All Other Contactless Devices in NIST’s Latest Contactless-to-Contact Fingerprint Capture Ranking
22.6.2020 11:00:00 EEST | Business Wire | Press release
IDEMIA today announced that its MorphoWave TM contactless fingerprint technology outperformed all other devices in the National Institute of Standards and Technology (NIST)’s latest Accuracy and Interoperability Test on all criteria involved.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005215/en/
(Photo Business Wire)
The primary reason for carrying out the “ Interoperability Assessment 2019: Contactless-to-Contact Fingerprint Capture ” study was to test how well touchless systems work with legacy databases. NIST tested six sold contactless fingerprint scanning technologies by comparing how they fared with conventional touch-based fingerprint devices. The results show that contactless devices that scanned multiple fingers consistently achieved better accuracy than single finger scanning and made less “false positive” errors that incorrectly matched a person’s print with someone else’s.
MorphoWave TM is a stand-out IDEMIA-developed technology that scans and checks four fingerprints in under a second by just waiving your hand within the reader. Shown as Dev03 in the report, MorphoWave TM consistently performs better than other contactless devices in terms of matching rate, image capture sample rate, areas of overlap between probe and exemplar fingerprints, finger ridges and minutiae similarity. Further testing was conducted with both contact and contactless probes matched to the MorphoWave TM exemplar contactless fingerprints.
This testing confirms MorphoWave TM, which already underpins the currently sold MorphoWave TM Compact, works well with legacy touch fingerprint scanners and other contactless solutions alike. It also highlights that this technology enables extremely efficient contactless fingerprint capture and matching against existing contact-based fingerprint databases. This latter feature is very beneficial for some government programs, border checks and minimizing passenger lines whenever user fingerprints are already held in a database. So MorphoWave TM gives passengers a smoother and more hygienic user experience.
IDEMIA CTO Jean-Christophe Fondeur said: “The recent COVID19 pandemic has ushered in growing demand for contactless and hygienic solutions. We are delighted to see contactless fingerprint capture that we pioneered is on the cusp of matching contact-based accuracy, and of course that our MorphoWave TM technology has emerged from this NIST interoperability test as the best in the industry. Given its outstanding capacity as borne out by this NIST test, our MorphoWave TM Compact is a game changer and will seamlessly raise hygiene standards in a vast array of environments including corporate offices, stores, airports, theme parks and leisure and entertainment venues.”
About NIST :
Founded in 1901, NIST is a non-regulatory federal agency within the U.S. Department of Commerce. NIST's mission is to promote U.S. innovation and industrial competitiveness by advancing measurement science, standards, and technology in ways that enhance economic security and improve our quality of life.
From smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials and computer chips, innumerable products and services rely in some way on technology, measurement, and standards provided by the National Institute of Standards and Technology.
Link to Interoperability Assessment 2019: Contactless-to-Contact Fingerprint Capture study: https://nvlpubs.nist.gov/nistpubs/ir/2020/NIST.IR.8307.pdf
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005215/en/
Contact information
PR firm: Havas Paris
Hanna Sebbah
+33 (6) 63 73 30 30.
idemia@havas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
